Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists

Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists

BACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006.

Bibliographic Details
Main Authors: J Jones, R Panaccione, ML Russell, R Hilsden
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Canadian Journal of Gastroenterology
Online Access:http://dx.doi.org/10.1155/2011/837847
id doaj-c2577c537f18471fb5cdf745344054ca
record_format Article
spelling doaj-c2577c537f18471fb5cdf745344054ca2020-11-24T21:27:36ZengHindawi LimitedCanadian Journal of Gastroenterology0835-79002011-01-01251056556910.1155/2011/837847Medical Management of Inflammatory Bowel Disease among Canadian GastroenterologistsJ Jones0R Panaccione1ML Russell2R Hilsden3Departments of Medicine and Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, CanadaDepartment of Medicine, University of Calgary, Calgary, Alberta, CanadaDepartment of Community Health Sciences, University of Calgary, Calgary, Alberta, CanadaDepartment of Medicine, University of Calgary, Calgary, Alberta, CanadaBACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006.http://dx.doi.org/10.1155/2011/837847
collection DOAJ
language English
format Article
sources DOAJ
author J Jones
R Panaccione
ML Russell
R Hilsden
spellingShingle J Jones
R Panaccione
ML Russell
R Hilsden
Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
Canadian Journal of Gastroenterology
author_facet J Jones
R Panaccione
ML Russell
R Hilsden
author_sort J Jones
title Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
title_short Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
title_full Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
title_fullStr Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
title_full_unstemmed Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
title_sort medical management of inflammatory bowel disease among canadian gastroenterologists
publisher Hindawi Limited
series Canadian Journal of Gastroenterology
issn 0835-7900
publishDate 2011-01-01
description BACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006.
url http://dx.doi.org/10.1155/2011/837847
work_keys_str_mv AT jjones medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists
AT rpanaccione medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists
AT mlrussell medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists
AT rhilsden medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists
_version_ 1725974641563926528

Similar Items